Bill or resolution detail
HR 7640
To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").
Record identity
Official facts
These fields are copied from the synchronized official record.
Referred to the House Committee on Energy and Commerce.
Copied official fact
Deterministic classification
Lifecycle
This section is generated by FederalStateData from accepted bill actions and remains labeled as derived.
CompleteThis section satisfies its canonical contract.1 records · synchronized Aug 3, 2026, 2:35 AM
FederalStateData derivedReferredMedium confidenceUnreviewed
Referred to the House Committee on Energy and Commerce.
Effective Apr 7, 2025Entity 117-hr-7640
Official sponsorship relationships
Sponsors and cosponsors
CompleteThis section satisfies its canonical contract.2 records · synchronized Not available
| Member | Party | Role | Sources |
|---|---|---|---|
| Gus M. Bilirakis | Republican Party | PRIMARY | |
| G. K. Butterfield | Democratic Party | COSPONSOR |
Official chronology
Actions
CompleteThis section satisfies its canonical contract.2 records · synchronized May 3, 2022, 12:00 AM
May 3, 2022 · IntroReferral
Introduced in House
Chamber not specifiedOfficial action ↗
May 3, 2022 · IntroReferral
Referred to the House Committee on Energy and Commerce.
Chamber not specifiedOfficial action ↗
Official text changes
Amendments
CompleteThis section satisfies its canonical contract.0 records · synchronized Not available
No amendments are attached.
Referral and jurisdiction
Committees
CompleteThis section satisfies its canonical contract.1 records · synchronized Not available
| Committee | Chamber | Relationship | Source |
|---|---|---|---|
| Energy and Commerce Committeehsif00 | HOUSE | REFERRED | Official relationship ↗ |
Official roll calls
Votes
CompleteThis section satisfies its canonical contract.0 records · synchronized Not available
No roll-call votes are attached.